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Abstract
Philadelphia chromosome-positive chronic myelogenus leukemia (CML) is widely treated with
imatinib mesylate (imatinib), a potent inhibitor of the Bcr-Abl tyrosine kinase. However, resistance
to this compound remains a concern. Current treatment approaches include combinations of imatinib
with nucleoside analogs such as gemcitabine, which requires equilibrative nucleoside transporters
(ENTs) for uptake, to overcome this resistance. Here we report that imatinib treatment decreased
ENT1-dependent activity and mRNA expression. Although, imatinib-resistant cells showed
decreased levels of both ENT1 and ENT2 activity and expression, these cells remained sensitive to
gemcitabine, suggesting that nucleoside analogs can be used as adjunctive therapy.
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Introduction
The underlying cause of chronic myeloid leukemia (CML) is the product of Philadelphia
chromosome (Ph), the Bcr-Abl fusion protein, which presents a constitutively activated Abl
tyrosine kinase activity. Treatment of Ph positive (Ph+) CML has centered on strategies that
suppress the Ph+ cells or the Ph-associated Bcr-Abl molecular abnormalities.[1,2]CML is
widely treated with the Bcr-Abl selective tyrosine kinase inhibitor, imatinib mesylate (imatinib,
Gleevec, STI571).[3,4] However, resistance to imatinib, particularly in the advanced phases
of CML and Ph+ acute lymphoblastic leukemia (ALL) is very common. Thus, it is crucial to
develop new strategies of treatment to overcome or avoid the development of resistance.
Current treatment approaches include the combination of treatments using imatinib and
compounds such as interferon-α (IFN-α), hemoharringtonine (HHT) and nucleoside analogs
such as cytarabine and gemcitabine.[5–8]
Mammalian equilibrative nucleoside transporters (ENTs) are facilitative transporters broadly
selective for pyrimidine and purine nucleosides and are essential for the modulation of
nucleoside concentration and nucleoside analog availability. Uptake of clinically important
nucleoside analogs (e.g., gemcitabine, capecitabine, cytarabine (ara-C)) is mediated primarily
by Equilibrative Nucleoside Transporter 1 (hENT1) in human cells.[9] The development of
resistance to both gemcitabine and capecitabine correlates strongly with a deficiency of ENT1
expression in human breast cancer cells[10] and resistance to ara-C has been attributed to
reduced expression of ENT1 in acute myeloid leukemia cells.[11]
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We report here that Bcr-Abl mouse cells, 32Dp185 cells, treated with imatinib showed
decreased mENT1 transport activity and mRNA expression in a time-dependent manner.
Interestingly, although the imatinib-resistant cells showed low ENT activity and expression,
these cells remained sensitive to the nucleoside analog gemcitabine. Thus, our results show
that resistance to imatinib may not alter the sensitivity to nucleoside analogs, suggests that
cotreatment with nucleoside analogs and imatinib in CML may prove effective in reducing the
development and consequences of resistance to the latter agent.
Materials and Methods
Cell Culture and Reagents
Mouse 32Dp185 cells were grown in RPMI 1640 supplemented with 10% heat inactivated
fetal bovine serum (FBS) and 100 units/ml penicillin and 100 mg/ml streptomycin. Cells were
maintained in the presence 5% CO2 at 37°C. NBMPR (nitrobenzymercaptopurine, 6-[(40
nitrobenzyl)thio]-9-(b-D-ribofuranosyl)purine), was from Sigma (Sigma-Chemical Co., St.
Louis, MO, USA). Uridine ([5,6-3H], 35-60 Ci/mmol) and [3H]-NBMPR 40 Ci/mmol were
purchased from Moravek Biochemicals and Radiochemicals (Brea, CA., USA). STI-571
(Imatinib mesylate, Figure 1a) was from Toronto Research Chemicals (North York, ON,
Canada). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole)
was obtained from Promega (Madison, WI, USA) and the assay was performed according to
the manufacturer's instructions.
Generation of the Imatinib-Resistant 32Dp185 Cell Line (32Dp185 STI-R)
Mouse 32Dp185 cells were exposed to increasing concentrations of imanitib for several weeks
(0.1–1 μM). The cells were maintained at a constant imanitib final concentration of 1 μM in
RPMI 1640 supplemented with 10% heat inactivated FBS and 100 units/ml penicillin and 100
mg/ml streptomycin.
ENT1- and ENT2-Dependent[3H]-Uridine Uptake Assay
Equal amounts of cells were used for the uptake of uridine. The assay was performed as
described previously.[12]After the uptake assay the cells were lysed in 800 μl lysis buffer
containing 20 mM Tris-HCl pH 7.5, 137 mM NaCl, 1% Triton X-100, 10% glycerol and 2 mM
EDTA. After centrifugation at 10,000g for 10 minutes at 4°C, 600 μl of supernatant were use
to measure for radioactivity and 200 μl were used to measure protein concentration.
Real Time PCR
Total RNA was extracted using Trizol (Invitrogen) according manufacturer's instructions. Two
μg RNA were used for cDNA synthesis using SuperScriptII reverse transcriptase (Invitrogen)
according to manufacturer's protocol. Expression level for mENT1 was quantified by real-time
PCR (7500 Fast Real-Time PCR System, Applied Biosystems, Foster City, CA, USA)
according to the manufacturer's instructions. The PCR reaction mixtures contained 900 nM
each of the sense primer (5′ATGGCAAGGGCTCAATGG-3′) and antisense primer (5′-
TGGAGTAAGCGGGCATCAGT-3′) for mENT1, sense primer (5′-
GCTGTGCCTTGTGTTGGTCTT-3′) and antisense primer (5′-
ATGGCTGTGATGGCAGGAA-3′) for mENT2 or 900 nM each of the sense primer (5′-
TGAAGCAGGCATCTGAGGG-3′) and antisense primer (5′-
CGAAGGTGGAAGAGTGGGAG-3′) for the mouse housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase, mGAPDH. One hundred ng cDNA and SYBR Green PCR master
mix (Applied Biosystems) was also added to reaction mixtures. After initial 10 minutes
incubation at 95°C, cDNA was amplified using increasing cycles of 95°C for 15 seconds and
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60°C for 1 minute. Transcript levels and fold change in mRNA between treatments were
determined as previously described.[13]
Results
Imatinib Decreased ENT1 Transport Activity and Expression
In order to investigate the effects of imatinib on ENT1-dependent uridine uptake, we treated
32Dp185 cells with 1 μM imatinib. Our results showed a time-dependent decrease in ENT1-
dependent transport activity (Figure 1b). Quantitative RT-PCR (QRT-PCR) analysis of ENT1
mRNA expression showed a similar time-dependent down-regulation, suggesting that the
diminished transport activity was due to a repression in ENT1 expression (Figure 1c).
Imatinib-Resistant Cells Show Reduced ENT1 Transport Activity and Expression
To test if ENT1 activity and expression were affected in imatinib-resistant cells, we developed
an imatinib-resistant cell line derived from 32Dp185 cells (32Dp185 STI-R), as described in
Materials and Methods. ENT1- and ENT2-dependent uridine uptake was diminished in the
32Dp185 STI-R cells (60 and 40%, respectively) compared to the parental cells (Figures 2a
and 2b). Moreover, QRT-PCR data indicated that this decrease in uridine uptake was most
likely due to a diminished mRNA expression of both ENT isoforms (Figures 2c and 2d).
Imatinib-Resistant Cells Are Less Sensitive to Nucleoside Analogs Treatments
Nucleoside analogs as gemcitabine and araC are potential drugs to be used alone or in
combination with imatinib for the treatment of CML.[6,7] These nucleoside analogs are
transported into cells mainly through ENTs. To investigate whether imatinib-resistant cells
showed reduced sensitivity to gemcitabine (structure shown in Figure 3a), we incubated
32Dp185 and 32Dp185 STI-R cells with 1 μM gemcitabine for 12 hours and performed MTT
assays. The results in Figure 3b show that both cell lines were equally sensitive to gemcitabine
treatment.
Discussion
The results presented here define an important role of Bcr-Abl kinase in ENT1 expression and
ENT1-dependent uridine transport. We showed that imatinib treatment down regulated ENT1
expression as well as the ENT1-dependent uridine uptake. Moreover, the imatinib-resistant
cell line, 32Dp185 STI-R, exhibited decreased ENT1 and ENT2 activities and expression,
suggesting that Bcr-Abl leukemic cells that are resistant to imatinib will also be resistant to
nucleoside analogs. However, contrary to our prediction, we observed a similar rate of cell
death in imatinib-resistant cells when exposed to the nucleoside analog gemcitabine. These
results suggest that in imatinib-resistant cells a compensatory mechanism may exist for
gemcitabine uptake when ENT1 and ENT2 are downregulated. Alternatively the amount of
ENT-dependent activity remaining in these cells is sufficient to accommodate gemcitabine
uptake.
The concentrative nucleoside transporters (CNTs) transport nucleosides against their
concentration gradients by coupling the inward transport of nucleosides to the electrochemical
Na+ gradients.[4] While CNT1 and CNT2 expression is limited to certain tissues including
kidney, intestine and liver, CNT3 is found in a wider variety of tissues, suggesting that it plays
multiple roles in nucleoside homeostasis.[15] Both CNT1 and CNT3 can transport gemcitabine
with high affinity.[16,17] Moreover, it was previously reported that expression of hCNT1 in
pancreatic cancer cells with a stable expression of hENT1 were more sensitive to gemcitabine
treatments than cells with lower expression of CNT1 and the same levels of hENT1.[18] Thus,
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it is possible that CNTs may contribute to the uptake of gemcitabine under our experimental
conditions.
We report here that resistance to imatinib induced an ENT1 and ENT2 expression down-
regulation; however, the sensitivity to the nucleoside analog gemcitabine was maintained.
These results suggest that nucleoside analogs may be used as a combination therapy in imatinib-
resistant CML.
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Imantinib decreased ENT1-dependent uridine uptake and mRNA expression. (a) Structure of
imatinib mesylate. 32Dp185 cells were incubated with 1 μM imatinib for the times indicated.
The values shown in the graphs represent means ± S.D. of data from a representative experiment
(n = 3). (b) 3[H]-Uridine uptake was measured as described in the Materials and Methods
section. (c) Real Time PCR was performed to quantify the relative change in mENT1 transcript
after treatments for the times indicated. Asterisks indicate statistical significance (*p < 0.05,
**p < 0.01 Student's t test).
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Imatinib-resistant cells exhibit decrease ENT1- and ENT2-dependent uridine uptake and
mRNA expression. The values shown in the graphs represent means ± S.D. of data from a
representative experiment (n = 3). (a) ENT1-dependent 3[H]-uridine uptake and (b) ENT2-
dependent 3[H]-uridine uptake was measured in 32Dp185 and 32Dp185 STI-R cells as
described in Materials and Methods. Real Time PCR was performed to quantify the relative
amounts of (c) mENT1 and (d) mENT2 transcripts. Asterisks indicate statistical significance
(*p < 0.05, **p < 0.01 Student's t test).
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Imatinib-resistant cells exhibit the same sensitivity to nucleoside analogs. (a) Structure of
gemcitabine. (b) MTT assay was performed in 32Dp185 and 32Dp185 STI-R cells treated for
12 hours with 1 μM gemcitabine (Gem). The values shown are means ± S.D. of data from a
representative experiment (n = 3). Asterisks indicate statistical significance (**p < 0.01
Student's t test).
Leisewitz et al. Page 8
Nucleosides Nucleotides Nucleic Acids. Author manuscript; available in PMC 2009 June 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
